Title:
LIPID MEMBRANE STRUCTURE FOR DELIVERING NUCLEIC ACID TO WITHIN CELL
Document Type and Number:
WIPO Patent Application WO/2019/103151
Kind Code:
A1
Abstract:
[Problem] The purpose of the present invention is to provide a novel intracellular delivery means for delivering a nucleic acid to within a cell and thereby causing a desired function to be exhibited more efficiently, namely, for delivering a nucleic acid to within an antigen-presenting cell and thereby increasing the antigen presentation strength of a transfected cell. [Solution] Provided is a lipid membrane structure that is for delivering a nucleic acid to within a cell, in which a lipid membrane is modified by at least one polypeptide having 12-50 amino acid residues including at least three K-A-L-A repeating units within the peptide chain thereof (wherein K may be R in one or more of the repeating units, and/or the A sandwiched between K and L may be H in one or more of the repeating units), and wherein a nucleic acid is held on the surface of the lipid membrane structure.
Inventors:
AKITA HIDETAKA (JP)
MIURA NAOYA (JP)
TATESHITA NAHO (JP)
TANAKA HIROKI (JP)
MIURA NAOYA (JP)
TATESHITA NAHO (JP)
TANAKA HIROKI (JP)
Application Number:
PCT/JP2018/043528
Publication Date:
May 31, 2019
Filing Date:
November 27, 2018
Export Citation:
Assignee:
UNIV CHIBA NAT UNIV CORP (JP)
International Classes:
C12N15/11; A61K9/127; A61K35/15; A61K39/00; A61K39/39; A61K47/62; A61K47/69; A61P37/04; C07K17/02; C07K7/08; C07K14/00; C12N5/10; C12N15/09
Domestic Patent References:
| WO2011132713A1 | 2011-10-27 | |||
| WO2015098907A1 | 2015-07-02 | |||
| WO2016190940A1 | 2016-12-01 | |||
| WO2005120574A1 | 2005-12-22 | |||
| WO2013073480A1 | 2013-05-23 |
Other References:
MIYAURA, NAOYA: "Dendritic cell engineering based on nano-DNA vaccine, and its deployment for refractory cancer treatment", GRANTS-IN-AID FOR SCIENTIFIC RESEARCH DATABASE, 24 January 2019 (2019-01-24), XP055616189, Retrieved from the Internet
VERBEKE, R. ET AL.: "Co-delivery of nucleoside- modified mRNA and TLR agonists for cancer immunotherapy: Restoring the immunogenicity of immunosilent mRNA", JOURNAL OF CONTROLLED RELEASE, vol. 266, 5 October 2017 (2017-10-05), pages 287 - 300, XP085292759, DOI: 10.1016/j.jconrel.2017.09.041
HEIDARI, Z. ET AL.: "Impact of the Charge Ratio on the In Vivo Immunogenicity of Lipoplexes", PHARM RES, vol. 34, no. 9, 30 May 2017 (2017-05-30), pages 1796 - 1804, XP036287140, DOI: 10.1007/s11095-017-2187-2
MASSEY, A. S. ET AL.: "Potentiating the Anticancer Properties of Bisphosphonates by Nanocomplexation with the Cationic Amphipathic Peptide, RALA", MOLECULAR PHARMACEUTICS, vol. 13, 8 March 2016 (2016-03-08), pages 1217 - 1228, XP055616194, DOI: 10.1021/acs.molpharmaceut.5b00670
MIURA, NAOYA: "Development of vaccine technology based on KALA peptide modified nanoparticles and its application to cancer immunotherapy", HOKKAIDO UNIVERSITY COLLECTION OF SCHOLARLY AND ACADEMIC PAPERS, 22 March 2018 (2018-03-22), XP055616199, Retrieved from the Internet [retrieved on 20190124]
VERBEKE, R. ET AL.: "Co-delivery of nucleoside- modified mRNA and TLR agonists for cancer immunotherapy: Restoring the immunogenicity of immunosilent mRNA", JOURNAL OF CONTROLLED RELEASE, vol. 266, 5 October 2017 (2017-10-05), pages 287 - 300, XP085292759, DOI: 10.1016/j.jconrel.2017.09.041
HEIDARI, Z. ET AL.: "Impact of the Charge Ratio on the In Vivo Immunogenicity of Lipoplexes", PHARM RES, vol. 34, no. 9, 30 May 2017 (2017-05-30), pages 1796 - 1804, XP036287140, DOI: 10.1007/s11095-017-2187-2
MASSEY, A. S. ET AL.: "Potentiating the Anticancer Properties of Bisphosphonates by Nanocomplexation with the Cationic Amphipathic Peptide, RALA", MOLECULAR PHARMACEUTICS, vol. 13, 8 March 2016 (2016-03-08), pages 1217 - 1228, XP055616194, DOI: 10.1021/acs.molpharmaceut.5b00670
MIURA, NAOYA: "Development of vaccine technology based on KALA peptide modified nanoparticles and its application to cancer immunotherapy", HOKKAIDO UNIVERSITY COLLECTION OF SCHOLARLY AND ACADEMIC PAPERS, 22 March 2018 (2018-03-22), XP055616199, Retrieved from the Internet
Attorney, Agent or Firm:
IP-ASSIST PATENT OFFICE (JP)
Download PDF: